Illinois 104th General Assembly Status: Introduced 1 D cosponsors

SB3337      — DPH-LUNG CANCER STUDY

Last action — Rule 3-9(a) / Re-referred to Assignments

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill has been introduced in the Senate. Introduced February 04, 2026. It must pass committee before a floor vote.

Next likely step: a committee referral and hearing.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Not enough signal yet

Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

In plain language

This bill allows a study on lung cancer biomarkers by the Department of Public Health.

The bill amends existing law to authorize the Department of Public Health to conduct a study focused on lung cancer biomarkers. The study will explore genetic variations linked to risks, treatment resistance, and disease subtypes in lung cancer.

What this means for you
  • Consumers: Consumer understanding of lung cancer risks and treatments may improve with findings from the study.
  • Healthcare: The bill may lead to new insights into lung cancer treatment and prevention for healthcare providers.

Summary

Amends the Department of Public Health Powers and Duties Law of the Civil Administrative Code of Illinois. Authorizes the Department of Public Health to conduct a study on lung cancer biomarkers, including, but not limited to, the anaplastic lymphoma kinase gene. Provides that the study may focus on identifying genetic variations in lung cancer that are linked to increased risks, genetic variations that are linked to treatment resistance, and genetic variations that are linked to specific disease subtypes. Provides that the Department of Public Health may enter into contracts, grants, or other agreements for the purpose of completing the study. Provides for the repeal of these provisions on January 1, 2029.

Bill Text

We don't have the full text on file for this bill yet.

Read SB3337 on the official Illinois source →

Action History

  1. Rule 3-9(a) / Re-referred to Assignments

  2. Rule 2-10 Committee/3rd Reading Deadline Established As May 22, 2026

  3. Rule 2-10 Committee/3rd Reading Deadline Established As May 15, 2026

  4. Rule 2-10 Committee Deadline Established As April 24, 2026

  5. Assigned to Appropriations- Health and Human Services

  6. Referred to Assignments

  7. First Reading

  8. Filed with Secretary by Sen. Adriane L. Johnson

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 182 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (182)

182 members have not signed on to this bill.

Show all 182 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB3337      do?
Amends the Department of Public Health Powers and Duties Law of the Civil Administrative Code of Illinois. Authorizes the Department of Public Health to conduct a study on lung cancer biomarkers, including, but not limited to, the anaplastic lymphoma kinase gene. Provides that the study may focus on identifying genetic variations in lung cancer that are linked to increased risks, genetic variations that are linked to treatment resistance, and genetic variations that are linked to specific disease subtypes. Provides that the Department of Public Health may enter into contracts, grants, or other agreements for the purpose of completing the study. Provides for the repeal of these provisions on January 1, 2029.
Who sponsors SB3337     ?
SB3337      is sponsored by Adriane L. Johnson (Democrat).
What is the current status of SB3337     ?
This bill has been introduced in the Senate. Introduced February 04, 2026. It must pass committee before a floor vote.
Where can I track SB3337     ?
Track SB3337      free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB3337     

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB3337     

Last checked for changes about 2 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →